Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 30, 2015 10:52 PM ET


Company Overview of OvaScience, Inc.

Company Overview

OvaScience, Inc., a life science company, engages in the discovery, development, and commercialization of new treatments for infertility. The company’s patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman's own ovaries. It is developing and commercializing various fertility treatment options designed to enhance egg health and revolutionize in vitro fertilization (IVF) comprising AUGMENT to improve the energy and health of the woman’s eggs by using mitochondria from a woman's EggPC cells; OvaPrime treatment for boosting a woman's egg reserve by transferring the EggPCs from woman's own ovaries;...

215 First Street

Suite 240

Cambridge, MA 02142

United States

Founded in 2011

52 Employees



Key Executives for OvaScience, Inc.

Co-Founder, Chief Executive Officer and Director
Age: 39
President and Chief Scientific Officer
Total Annual Compensation: $644.0K
Chief Commercial Officer
Age: 49
Total Annual Compensation: $21.1K
Compensation as of Fiscal Year 2014.

OvaScience, Inc. Key Developments

OvaScience, Inc. Announces Resignation of David Harding, Chief Commercial Officer

On August 27, 2015, David Harding and OvaScience, Inc. mutually agreed that Mr. Harding will resign as Chief Commercial Officer of the company effective August 28, 2015 to pursue other opportunities.

OvaScience, Inc. - Special Call

To consider the publication of analyses of the AUGMENTSM treatment and other recent business updates, including geographic expansion

OvaScience Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

OvaScience reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company announced net loss of $17.5 million, or $0.64 per basic and diluted share, as compared to net loss of $9.9 million, or $0.42 per basic and diluted share, a year ago. The company announced revenues of $30,000, loss from operations of $17,174,000 compared to $9,595,000 a year ago. The increase in net loss is primarily attributable to stock-based compensation, planned higher personnel costs, and costs associated with the launch of the AUGMENT treatment in certain international IVF clinics. For the six months the company announced revenues of $45,000, loss from operations of $33,987,000, net loss of $34,696,000 or $1.29 per basic and diluted share against loss from operations of $17,245,000, net loss of $17,707,000 or $0.83 per basic and diluted share compared to previous year.

Similar Private Companies By Industry

Company Name Region
Syntimmune, Inc. United States
Syngenta Biotechnology, Inc. United States
CARR Separations Inc. United States
Pure Cultures LLC United States
Atterocor, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OvaScience, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at